Publications by authors named "Hun Mi Choi"
Article Synopsis
- The study investigates the effectiveness of repotrectinib, a new treatment for lung cancer, particularly against the common ROS1-G2032R mutation and brain metastases, which pose therapeutic challenges.
- In preclinical models, repotrectinib showed stronger anti-tumor effects compared to existing treatments like crizotinib and was notably effective at preventing tumor recurrence after treatment cessation.
- Results from an ongoing clinical trial support the potential of repotrectinib as a first-line therapy and for patients who have already progressed on previous ROS1-targeting treatments, demonstrating its ability to penetrate the blood-brain barrier effectively.
Clinical benefit of ALK tyrosine kinase inhibitors (ALK-TKIs) in ALK-rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass-molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA-approved drugs in ALK-TKI-resistant models. Cerivastatin, the rate-limiting enzyme inhibitor of the mevalonate pathway, showed anti-cancer activity against ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic retention and subsequent inactivation of transcriptional co-regulator YAP.
View Article and Find Full Text PDFBackground: Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy.
Methods: Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation.
Article Synopsis
- ALK inhibitors are effective for fusion-positive lung cancer but face issues with acquired resistance, which may involve not just genetic mutations but also epigenetic changes.
- Research showed that changes in histone H3K27ac and the remodeling of enhancers affected the expression of both miRNAs and mRNAs during the resistance development.
- Targeting epigenetic pathways, rather than solely focusing on genetic mutations, could provide new strategies to overcome resistance to cancer therapies, as demonstrated by the effects of panobinostat along with ALK inhibitors.